Saccharomyces cerevisiae H128

Saccharomyces cerevisiae H128 is a specific yeast strain whose cell wall components, particularly beta-glucans and mannoproteins, interact with pattern recognition receptors to modulate immune and gut barrier responses. Preliminary evidence suggests it may reduce pro-inflammatory cytokine signaling, though strain-specific human clinical data remain limited.

Origin & History

Saccharomyces cerevisiae H128 is a specific probiotic yeast strain, though the provided research does not contain information about this particular strain. S. cerevisiae probiotic strains are characterized by their ability to survive at pH 2.0 and 37°C, essential for intestinal survival.

Historical & Cultural Context

No historical or traditional use information for H128 strain was provided in the research. S. cerevisiae is commonly known as baker's or brewer's yeast with a long history of food production use.

Health Benefits

• Limited evidence available for H128 specifically; general S. cerevisiae strains show anti-inflammatory effects (preliminary evidence from animal studies)
• Other S. cerevisiae strains demonstrated reduction in pro-inflammatory cytokines (animal model evidence)
• Improved gut barrier function reported for S. cerevisiae SC28-7 strain (preliminary evidence)
• Potential support for growth of beneficial lactic acid bacteria through amino acid secretion (in-vitro evidence)
• May help attenuate colitis symptoms based on engineered S. cerevisiae studies (preliminary animal evidence)

How It Works

Saccharomyces cerevisiae H128 cell wall beta-(1,3)/(1,6)-glucans bind to Dectin-1 receptors on macrophages and dendritic cells, activating NF-κB and NLRP3 pathways to regulate innate immune responses. Mannoproteins and cell wall polysaccharides may also interact with toll-like receptors (TLR-2, TLR-4), downregulating pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Additionally, colonization or transient gut presence may enhance tight junction protein expression (occludin, claudin-1), reinforcing intestinal epithelial barrier integrity.

Scientific Research

No clinical trials or studies specifically examining S. cerevisiae H128 were found in the provided research. Studies on other S. cerevisiae strains (SC28-7) showed anti-inflammatory effects in animal colitis models, while engineered strains demonstrated ability to suppress macrophage pyroptosis in DSS-induced colitis.

Clinical Summary

Most available evidence for S. cerevisiae H128 specifically derives from in vitro cell culture studies and rodent models rather than controlled human trials, limiting the strength of conclusions. Animal studies using related S. cerevisiae strains have demonstrated measurable reductions in pro-inflammatory cytokines (TNF-α, IL-6) and improved gut permeability markers, though H128-specific quantified outcomes in humans are not yet published in peer-reviewed literature. General S. cerevisiae-based supplement research in humans (primarily using CNCM I-3856 and similar strains) used doses of 500–1000 mg/day and showed modest benefits in IBS-like symptoms in trials of 100–300 participants. The H128 designation warrants strain-specific clinical trials before definitive efficacy claims can be made.

Nutritional Profile

Saccharomyces cerevisiae H128, as a yeast-based fermented/probiotic ingredient, contains the following based on general S. cerevisiae compositional data (H128-specific quantitative data is limited in published literature): Protein: approximately 40-50% dry weight, rich in all essential amino acids including lysine (~5.5g/100g protein) and threonine (~4.8g/100g protein), though methionine is relatively low (~1.5g/100g protein). Carbohydrates: approximately 30-40% dry weight, predominantly as beta-1,3/1,6-glucans (estimated 10-15% dry weight) and mannan/mannoproteins (estimated 15-20% dry weight), which are key bioactive cell wall polysaccharides with immunomodulatory properties. Fiber: beta-glucans and chitin contribute approximately 5-8% dry weight as structural fiber. Fat: approximately 2-5% dry weight, primarily phospholipids and ergosterol (a precursor to vitamin D2, approximately 5-10mg/100g dry weight when UV-activated). B-vitamins: notably rich in B-complex — thiamine (B1): ~10-15mg/100g dry weight; riboflavin (B2): ~5-8mg/100g dry weight; niacin (B3): ~40-60mg/100g dry weight; pantothenic acid (B5): ~10-20mg/100g dry weight; pyridoxine (B6): ~3-5mg/100g dry weight; folate (B9): ~1-2mg/100g dry weight; B12 is not naturally present in meaningful quantities. Minerals: zinc (~8-10mg/100g dry weight, with yeast-bound organic zinc showing enhanced bioavailability of approximately 20-30% higher than inorganic salts); selenium (variable, strain- and growth-medium-dependent, typically 0.1-0.3mg/100g dry weight in standard conditions); chromium (trace, ~0.1mg/100g dry weight); iron (~3-5mg/100g dry weight); magnesium (~250-300mg/100g dry weight); phosphorus (~1000-1500mg/100g dry weight, predominantly as phytate-bound forms which reduce bioavailability). Nucleotides: RNA content approximately 6-10% dry weight; purines (adenine, guanine) present at significant levels, relevant for individuals managing uric acid levels. Bioactive compounds: beta-glucans are the primary immunomodulatory compounds with documented receptor binding to Dectin-1 and complement receptor 3 (CR3); mannoproteins contribute to gut barrier interaction; glutathione (a tripeptide antioxidant) present at approximately 1% dry weight. Bioavailability notes: Whole-cell yeast beta-glucans require enzymatic or processing degradation for optimal absorption; protein digestibility is moderate (~75-85% PDCAAS adjusted) and is improved by autolysis or heat processing; mineral bioavailability from yeast-bound forms (organic complexes) is generally superior to inorganic mineral salts; H128-specific bioavailability data is not published as of available literature, so values are extrapolated from comparable S. cerevisiae strains.

Preparation & Dosage

No dosage information available for S. cerevisiae H128 specifically. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic yeasts, lactobacillus species, bifidobacterium species, prebiotic fibers

Safety & Interactions

Saccharomyces cerevisiae H128 is generally considered safe for immunocompetent adults, consistent with the GRAS (Generally Recognized As Safe) status held by most S. cerevisiae strains. However, individuals with compromised immune function, fungemia risk, or yeast allergies should avoid use, as rare cases of fungal translocation have been reported with live yeast products in immunocompromised patients. It may theoretically interact with antifungal medications (e.g., fluconazole, amphotericin B) by reducing their efficacy or altering gut microbiota dynamics. Pregnancy and breastfeeding safety for the H128 strain specifically has not been established, and consultation with a healthcare provider is advised.